Modified Blood Cells for Multiple Sclerosis Antigen-Specific Tolerance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for multiple sclerosis (MS) are only partially effective in preventing relapses and do not consistently halt disease progression, often causing significant side effects due to non-specific immunomodulation, which can inhibit both pathogenic and beneficial immune cells.
Innovation Solution
A therapeutic strategy involving the systemic administration of blood cells chemically coupled with a mixture of synthetic myelin antigens to induce antigen-specific tolerance, specifically targeting autoreactive CD4+ T lymphocytes, thereby rendering them non-functional or anergic.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-specific immunomodulating or immunosuppressive strategies are used to treat MS, then relapse prevention is partially achieved, but beneficial immune cells are inhibited along with pathogenic cells
Solution Approach 1:
The invention segments the immune response by targeting only pathogenic autoreactive T cells through antigen-specific tolerance induction, while leaving beneficial immune cells unaffected. This is achieved by using autologous antigen-presenting cells pulsed with specific myelin peptides to selectively induce tolerance to encephalitogenic epitopes without global immunosuppression
Solution Approach 2:
The invention applies local quality by making the immunomodulation effect specific to certain immune cell populations (autoreactive CD4+ T cells) rather than affecting all immune cells uniformly. The antigen-specific tolerance protocol creates a localized effect on pathogenic cells while preserving the function of regulatory and protective immune cells
2Duration of action of stationary object
If current immunosuppressive therapies are administered for long periods, then disease progression is partially controlled, but considerable side effects occur
Solution Approach 1:
The invention employs preliminary action by inducing antigen-specific tolerance that can lead to long-lasting or permanent suppression of pathogenic T cell responses. The single administration of tolerized antigen-presenting cells creates enduring immunological memory that prevents relapses without requiring continuous long-term immunosuppressive therapy
Solution Approach 2:
The invention uses a single administration of tolerized autologous antigen-presenting cells that exert their effect and are then cleared by the body. This disposable approach avoids the need for continuous administration of immunosuppressive drugs, thereby reducing cumulative side effects while maintaining therapeutic efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively attenuates the pathogenic autoimmune response with minimal side effects by inducing tolerance to autoantigens, demonstrated to be safe and effective in animal models and early clinical trials, potentially reducing disease progression and relapses in MS patients.
Implementation Method 1
systemic administration of blood cells chemically coupled with a mixture of synthetic myelin antigens
Data Source
AI summary
The present invention describes blood cells chemically coupled with immunodominant myelin peptides and their use in the treatment of Multiple Sclerosis.